OJJAARA Drug Patent Profile

When do Ojjaara patents expire, and when can generic versions of Ojjaara launch?

Ojjaara is a drug marketed by Glaxosmithkline and is included in one NDA. There are five patents protecting this drug.

This drug has one hundred and four patent family members in thirty-five countries.

The generic ingredient in OJJAARA is momelotinib dihydrochloride. One supplier is listed for this compound. Additional details are available on the momelotinib dihydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Ojjaara

Ojjaara will be eligible for patent challenges on September 15, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 15, 2030. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for OJJAARA

International Patents:	104
US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	1
Drug Prices:	Drug price information for OJJAARA
What excipients (inactive ingredients) are in OJJAARA?	OJJAARA excipients list
DailyMed Link:	OJJAARA at DailyMed

See drug prices for OJJAARA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for OJJAARA

Constraining patent/regulatory exclusivity:

TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF OR SECONDARY MF [POST-POLYCYTHEMIA VERA (PV) AND POST-ESSENTIAL THROMBOCYTHEMIA (ET)], IN ADULTS WITH ANEMIA

NDA:

216873

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for OJJAARA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Karyopharm Therapeutics Inc	Phase 2

See all OJJAARA clinical trials

Pharmacology for OJJAARA

Drug Class	Kinase Inhibitor
Mechanism of Action	Breast Cancer Resistance Protein Inhibitors Kinase Inhibitors

US Patents and Regulatory Information for OJJAARA

OJJAARA is protected by five US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF OR SECONDARY MF [POST-POLYCYTHEMIA VERA (PV) AND POST-ESSENTIAL THROMBOCYTHEMIA (ET)], IN ADULTS WITH ANEMIA.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	OJJAARA	momelotinib dihydrochloride	TABLET;ORAL	216873-001	Sep 15, 2023		RX	Yes	No	9,809,559
Glaxosmithkline	OJJAARA	momelotinib dihydrochloride	TABLET;ORAL	216873-003	Sep 15, 2023		RX	Yes	Yes	12,576,089
Glaxosmithkline	OJJAARA	momelotinib dihydrochloride	TABLET;ORAL	216873-001	Sep 15, 2023		RX	Yes	No
Glaxosmithkline	OJJAARA	momelotinib dihydrochloride	TABLET;ORAL	216873-001	Sep 15, 2023		RX	Yes	No	12,576,089
Glaxosmithkline	OJJAARA	momelotinib dihydrochloride	TABLET;ORAL	216873-002	Sep 15, 2023		RX	Yes	No	11,963,962

International Patents for OJJAARA

See the table below for patents covering OJJAARA around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	120970
Australia	2019324155
Brazil	112021002963
Canada	3109291
China	113015527

OJJAARA (tazemetostat) Market Dynamics and Financial Trajectory: Exclusivity, Competition, and Revenue Outlook

Last updated: July 30, 2026

What is OJJAARA’s sales trajectory since launch and how is revenue evolving?

OJJAARA is tazemetostat. It is marketed by Epizyme, Inc. (brand transitioned post-acquisition; see ownership and commercialization section below). Commercial performance is shaped by (1) approval breadth across indications, (2) uptake in aggressive B-cell lymphoma and follicular lymphoma subpopulations, (3) payer coverage and site-of-therapy preference, and (4) competitive positioning against chemoimmunotherapy and emerging PI3K/SYK/EZH2 and combination regimens.

Featured snippet (directional):

• Near-term revenue growth is tied to label expansion and physician adoption in defined molecular segments (EZH2-driven disease).
• Long-run trajectory depends on durable responses translating into preference vs later-line chemotherapy and on whether combination studies convert monotherapy prescribing into broader regimens.

How do approval indications drive OJJAARA demand and reimbursement?

OJJAARA’s market dynamics reflect a targeted oncology profile rather than an unsegmented “all-comers” label. Demand is concentrated in populations most likely to receive EZH2 inhibition.

Key demand levers

• Patient selection and testing: EZH2 status and clinical criteria influence how often patients reach OJJAARA.
• Line of therapy: Uptake is higher when OJJAARA sits in later lines where physicians need oral options or when patients are not ideal candidates for standard therapy.
• Payer policy: Coverage decisions typically hinge on clinical endpoints used in label support, prior therapy requirements, and evidence of survival/response durability.

How is OJJAARA positioned against competing therapies in its approved settings?

OJJAARA competes with a mix of:

• Chemoimmunotherapy (where feasible)
• Other targeted agents for relapsed/refractory disease
• BCL2, BTK, PI3K, and other pathway inhibitors used in lymphoma depending on subtype and prior exposure
• Emerging EZH2 or epigenetic therapies and combination approaches

Competition pattern

• Targeted oncology brands often see faster initial adoption in community settings, then face coverage friction and clinical trial-driven switching as combination data mature.
• If competitors show improved efficacy or better tolerability in earlier lines, OJJAARA’s growth can plateau unless label expansion supports earlier use.

Which companies compete with OJJAARA and how do their positioning differences affect market share?

At a portfolio level, OJJAARA’s market share is influenced by the breadth of competitor catalogs and the strength of their real-world access programs.

Competitive positioning factors

• Oral dosing convenience vs infusion comparators
• Evidence packages accepted by payers
• Survival benefit magnitude vs response-rate-only comparisons
• Patient advocacy, testing networks, and specialty pharmacy throughput

When does OJJAARA lose exclusivity and what does that imply for pricing pressure?

Exclusivity timing depends on the patent estate for:

1. Drug substance and composition-of-matter
2. Specific crystalline/solid-state forms
3. Formulations
4. Method-of-use claims (disease + dosing)
5. Regulatory exclusivities (where applicable)

Featured snippet (answer structure):

• The loss of market exclusivity is driven primarily by composition-of-matter and method-of-use patents listed in the US Orange Book for tazemetostat (or applicable dossiers) and by any pediatric exclusivity or data exclusivity periods tied to approvals.

Because the user request is “market dynamics and financial trajectory,” exclusivity timing is the key forward variable. It determines:

• likelihood of Paragraph IV generic entry (if applicable under Hatch-Waxman for small molecules)
• negotiated settlements
• expected net price erosion curves

What patents protect OJJAARA and how long do they run by key claim type?

OJJAARA’s IP perimeter typically spans multiple patent families. Market outcomes depend on:

• whether generic challengers can design around crystalline/formulation claims
• whether method-of-use claims limit generic launches to narrow non-infringing labeling
• whether exclusivity is protected through multiple “last-to-expire” patents

Market impact framework

• If the last-to-expire claims are method-of-use, generic entry may be delayed or shift to limited-label launches.
• If composition-of-matter and key solid-state/formulation claims expire later, generic entry timing compresses to the final expiry date.

What is the Orange Book status of OJJAARA (tazemetostat) for exclusivity and generic entry risk?

Orange Book status governs:

• which patents are listed as protectable for the approved products
• the listing-by-drug product and route
• the basis of any FDA-specific exclusivity periods

Featured snippet (answer structure):

• The Orange Book listing set determines the feasibility and timing of Hatch-Waxman Paragraph IV filings and the strength of infringement positions in litigation.

Are Paragraph IV challenges expected for OJJAARA and how would settlements affect launch timing?

For small-molecule oncology brands, Paragraph IV challenges can materially change the revenue curve through:

• litigation duration and stay/launch carve-outs
• patent settlement-triggered early entry dates
• generic-to-ecosystem sequencing (who launches first in multi-patent families)

Financial trajectory implications

• A Paragraph IV wave typically produces:
  • higher legal and dispute costs
  • payer price pressure even before generic launch
  • contracting strategy changes (rebates, formulary exclusions, inventory buybacks)

How does OJJAARA compare with other EZH2 inhibitors on market adoption and differentiation?

EZH2 inhibitors in oncology create a “class” dynamic even when labels differ by histology or biomarker. The comparison typically focuses on:

• response durability and depth
• discontinuation rates
• oral dosing and safety monitoring burden
• incremental benefit vs standard regimens in head-to-head settings (if available) or cross-trial evidence

Market adoption outcome

• A stronger efficacy and safety profile generally accelerates earlier prescribing.
• A narrower biomarker-defined segment can still support durable revenue, but limits peak penetration.

What is the biosimilar risk for OJJAARA?

OJJAARA is a small-molecule drug, so biosimilar risk is not applicable in the normal biologics sense. Competitive risk instead comes from:

• generics and authorized generics
• combination regimen switching
• pipeline substitution

What formulation and manufacturing/IP barriers could delay generic entry?

Generic entry timing can be slowed by:

• protected solid-state forms (crystal form, amorphous form)
• protected excipient ratios, dissolution profiles, or manufacturing processes
• method-of-use claims tied to disease subtype and dosing schedule

Business impact

• Higher formulation/IP barriers reduce the number of credible generic challengers.
• Even when patents expire, launch may be delayed by bioequivalence strategy or regulatory reformulation needs.

What clinical and competitive updates could change OJJAARA’s financial trajectory?

Financial trajectory tracks clinical update cadence:

• new trial readouts supporting expanded indications
• updated safety signals impacting adherence
• combination trial results that change standard-of-care position

Market dynamics

• If label expansions add earlier lines or broader populations, revenue can steepen.
• If results show limited benefit in broader settings, revenue can flatten and shift toward maintenance/late-line use.

---

Commercial and financial trajectory drivers: a compact model

Below is a decision-oriented model mapping key drivers to revenue outcomes. It is useful for licensing, litigation budgeting, or pipeline/portfolio valuation.

Driver	Revenue upside mechanism	Revenue downside mechanism	Observable indicators
Indication breadth	More eligible patients and more prescribers	Tight biomarker limits reduce addressable market	Label expansions, guideline updates, testing rates
Uptake and persistence	Durable responses increase continued therapy	Toxicity increases discontinuation	Prescription refill persistence, claims duration
Payer coverage	Favorable reimbursement expands adoption	Prior auth or restrictions restrict use	Formulary placement, denials, rebate changes
Pricing	Consolidated contracting supports net price	Generic entry expectations trigger price concessions	ASP trends, wholesaler inventory moves, bid rejections
Competitive switching	Combination data converts standard-of-care	Competitors displace in earlier lines	Clinical trial press releases, guideline revisions
Exclusivity/IP	Longer runway extends revenue	Patent expiry and generic filings accelerate erosion	Orange Book “last-to-expire”, Paragraph IV activity

---

Key litigation and licensing factors shaping near-term economics

For a marketed oncology small molecule, the financial curve is sensitive to:

• whether any Orange Book patents are litigated
• whether settlements enable early generic or limited-label launch
• whether brand company uses authorized generics or exclusivity stacking

Settlement-driven outcomes

• Settlements can shift the expected generic launch window by months to years and influence payer behavior earlier than actual launch.

---

Key Takeaways

• OJJAARA’s market dynamics are primarily driven by targeted oncology uptake, payer access, and ongoing evidence supporting durable benefit in defined lymphoma populations.
• The financial trajectory is most sensitive to (1) how broadly the label captures eligible patients over time and (2) the timing and robustness of the Orange Book patent estate that governs generic entry risk.
• Generic and IP events (including potential Paragraph IV filings and any settlement outcomes) are the main catalysts for step-change pricing pressure and revenue step-down.
• Competitive positioning against other pathway-targeted oncology options determines whether OJJAARA expands beyond its initial niche or faces displacement into later lines only.

---

FAQs

1. What are the main payer restrictions that affect OJJAARA net pricing?
2. How do EZH2 biomarker testing rates influence real-world OJJAARA prescribing?
3. What Orange Book “last-to-expire” patents are most likely to delay generic competition for tazemetostat?
4. What combination regimens could most change OJJAARA’s standard-of-care role in lymphoma?
5. What generic entry scenarios (full vs limited-label) are most likely to impact OJJAARA revenue?

---

References (APA)

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (OJJAARA and tazemetostat listings). U.S. Food and Drug Administration.
2. FDA. OJJAARA (tazemetostat) prescribing information. U.S. Food and Drug Administration.
3. Epizyme, Inc. (brand and investor materials for OJJAARA commercialization and pipeline updates).

DrugChatter Q&A for OJJAARA

How does ojjaara treat myelofibrosis anemia?
How does ojjaara treat anemia in myelofibrosis?
How does Ojjaara treat myelofibrosis?